120 related articles for article (PubMed ID: 8106908)
1. Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer.
Farris A; Bisail M; Sarobba MG; Sanna G; Scotto T; Valzelli S; Intini C
J Chemother; 1993 Oct; 5(5):344-7. PubMed ID: 8106908
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
4. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
Unsal M; Erturk D
Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
[TBL] [Abstract][Full Text] [Related]
6. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
7. Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.
Casadio M; Lelli G; Giordani S; Boltri B; Blotta A; Busutti L; Ramini R; Falcone F; Pannuti F
J Chemother; 1990 Jun; 2(3):199-202. PubMed ID: 2166145
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study.
Veronesi A; Cartei G; Crivellari D; Magri MD; Della Valentina M; Foladore S; Trovò MG; Nascimben O; Sibau A; Talamini R
Eur J Cancer; 1994; 30A(10):1474-8. PubMed ID: 7833105
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG
J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265
[TBL] [Abstract][Full Text] [Related]
10. [Nerve conduction velocity following high-dose vincristine in the treatment of small cell bronchial cancer].
Eich F; Emser W; Sybrecht GW
Pneumologie; 1990 Feb; 44 Suppl 1():574-5. PubMed ID: 2164202
[TBL] [Abstract][Full Text] [Related]
11. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
12. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
Navarro M; Mur E; Jolis L; Bellmunt J; Bodi R; Solé LA; Rubio D
Rev Clin Esp; 1991 Oct; 189(5):209-12. PubMed ID: 1666192
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
Littlewood TJ; Smith AP; Anderson G; Chappell AG; James KW
Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
17. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
[TBL] [Abstract][Full Text] [Related]
18. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.
O'Bryan RM; Crowley JJ; Kim PN; Epstein RB; Neilan B; Coltman CA; Stuckey WJ; Pazdur R
Cancer; 1990 Feb; 65(4):856-60. PubMed ID: 2153435
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
[TBL] [Abstract][Full Text] [Related]
20. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up.
Lassen U; Kristjansen PE; Osterlind K; Bergman B; Sigsgaard TC; Hirsch FR; Hansen M; Dombernowsky P; Hansen HH
Ann Oncol; 1996 Apr; 7(4):365-71. PubMed ID: 8805928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
